Equities analysts forecast that Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) will post earnings of ($1.52) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Agios Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.35) and the lowest estimate coming in at ($1.80). Agios Pharmaceuticals posted earnings per share of ($1.47) during the same quarter last year, which indicates a negative year over year growth rate of 3.4%. The firm is expected to announce its next earnings results on Thursday, August 3rd.
On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.33) per share for the current year, with EPS estimates ranging from ($7.39) to ($5.67). For the next financial year, analysts anticipate that the firm will post earnings of ($5.99) per share, with EPS estimates ranging from ($7.30) to ($4.69). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. The business had revenue of $10.51 million during the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The firm’s quarterly revenue was down 66.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.64) EPS.
A number of research analysts recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, June 11th. Credit Suisse Group restated an “outperform” rating and set a $61.00 price objective on shares of Agios Pharmaceuticals in a report on Tuesday, April 18th. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $62.88.
In other news, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $55.00, for a total value of $118,030.00. Following the sale, the insider now owns 8,410 shares of the company’s stock, valued at $462,550. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the business’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $50.87, for a total transaction of $101,740.00. Following the completion of the sale, the director now directly owns 90,197 shares in the company, valued at approximately $4,588,321.39. The disclosure for this sale can be found here. In the last three months, insiders sold 24,564 shares of company stock worth $1,282,249. 10.55% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System raised its stake in Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares during the period. Bank of Montreal Can raised its stake in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the period. Creative Planning raised its stake in Agios Pharmaceuticals by 1.4% in the second quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 228 shares during the period. Nationwide Fund Advisors raised its stake in Agios Pharmaceuticals by 5.2% in the first quarter. Nationwide Fund Advisors now owns 10,104 shares of the biopharmaceutical company’s stock valued at $590,000 after buying an additional 500 shares during the period. Finally, Teachers Advisors LLC raised its stake in Agios Pharmaceuticals by 2.3% in the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 666 shares during the period. 83.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down 0.07% during midday trading on Friday, hitting $57.77. 343,226 shares of the company traded hands. The stock’s 50-day moving average is $51.10 and its 200 day moving average is $49.19. The stock’s market capitalization is $2.78 billion. Agios Pharmaceuticals has a 12-month low of $35.84 and a 12-month high of $67.74.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Agios Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agios Pharmaceuticals Inc. and related companies.